Download PDF
Thromb Haemost 2014; 112(05): 1071-1075
DOI: 10.1160/th14-04-0357
Letters to the Editor
Schattauer GmbH

Tranexamic acid and fibrinogen restore clotting in vitro and in vivo in cardiac thrombus associated hyperfibrinolysis with overt bleedings

Michael Schwameis
1   Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
,
Johannes Thaler
2   Department of Internal Medicine I – Clinical Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
,
Andreas Schober
3   Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria
,
Christian Schörgenhofer
1   Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
,
Christiane Kulinna-Cosentini
4   Department of Radiology, Medical University of Vienna, Vienna, Austri
,
Anton Laggner
3   Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria
,
Martin Röggla
3   Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria
,
Bernd Jilma
1   Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
› Author Affiliations
Further Information

Publication History

Received: 16 April 2014

Accepted after major revision: 20 June 2014

Publication Date:
20 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Aulmann C. et al. A 65-year-old female patient with breast cancer accompanied by thrombocytopenia and hyperfibrinolysis. Der Internist 2007; 48: 1015-1019.
    CrossrefPubMedGoogle Scholar
  • 2 Wada Y. et al. Severe bleeding tendency caused by a rare complication of excessive fibrinolysis with disseminated intravascular coagulation in a 51-year-old Japanese man with prostate cancer: a case report. J Med Case Rep 2012; 6: 378.
    CrossrefPubMedGoogle Scholar
  • 3 Fiegl M. et al. Massive disseminated intravascular coagulation and hyperfibrinolysis in alveolar rhabdomyosarcoma: case report and review of the literature. Ann Hematol 1999; 78: 335-338.
    CrossrefPubMedGoogle Scholar
  • 4 Weltermann A. et al. Disseminated intravascular coagulation (DIG) with massive hyperfibrinolysis in metastatic uterine cancer. Observations on the effects on the coagulopathy of various treatments (a case report). Wiener Klin Wochenschr 1998; 110: 53-57.
    PubMedGoogle Scholar
  • 5 Wunderlich J, Thimme W. Consumption coagulopathy in a patient with metastatic renal carcinoma. Med Klinik 1976; 71: 912-916.
    PubMedGoogle Scholar
  • 6 Orgel M. et al. Severe hemorrhage in a patient with metastatic colorectal cancer. Deut Med Wochenschr 2012; 137: 1705+.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Zoller H, Gross W, Schreiner W. Hemorrhagic diathesis in patients with malignant neoplasms. Med Klinik 1979; 74: 1716-1720.
    PubMedGoogle Scholar
  • 8 Bredt J. Hyperfibrinolysis in prostatic carcinoma. Blut 1962; 8: 22-28.
    CrossrefPubMedGoogle Scholar
  • 9 Morrison JJ. et al. Association of cryoprecipitate and tranexamic acid with improved survival following wartime injury: findings from the MATTERs II Study. J Am Med Assoc Surg 2013; 148: 218-225.
    PubMedGoogle Scholar
  • 10 Keene DD. et al. Rotational thromboelastometry-guided trauma resuscitation. Curr Opin Crit Care 2013; 19: 605-612.
    PubMedGoogle Scholar
  • 11 Livingstone C. Tranexamic acid in patients with major injuries and blood loss. Emergency nurse : the journal of the RCN Accid Emerg Nurs Assoc 2013; 21: 24-26.
    PubMedGoogle Scholar
  • 12 Davenport R. Pathogenesis of acute traumatic coagulopathy. Transfusion 2013; 53 (Suppl. 01) 23S-27S.
    CrossrefPubMedGoogle Scholar
  • 13 Xiao FF. et al. Abnormality of blood coagulation indexes in patients with de novo acute leukemia and its clinical significance. J Exp Hematol (Chinese) 2013; 21: 300-304.
    PubMedGoogle Scholar
  • 14 Mitrovic M. et al. International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation >= 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia. Med Oncol 2013; 30: 478.
    CrossrefPubMedGoogle Scholar
  • 15 Thaler J. et al. Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. Thromb Res 2014; 133: 303-305.
    CrossrefPubMedGoogle Scholar
  • 16 Taylor Jr. FB. et al. Scientific Subcommittee on Disseminated Intravascular Coagulation of the International Society on T, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1327-1330.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Wada H. et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Hae-most 2013; 11: 761-767.
    CrossrefPubMedGoogle Scholar
  • 18 Spiel AO. et al. Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans. J Thromb Haemost 2006; 4: 411-416.
    CrossrefPubMedGoogle Scholar
  • 19 Derhaschnig U. et al. Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 2003; 102: 2093-2098.
    CrossrefPubMedGoogle Scholar
  • 20 Leitner JM. et al. Massive pulmonary embolism leading to cardiac arrest is associated with consumptive coagulopathy presenting as disseminated intravascular coagulation. J Thromb Haemost 2010; 8: 1477-1482.
    CrossrefPubMedGoogle Scholar
  • 21 Technoclone GmbH V Austria. Normotest®. 2011 12/2011.
    PubMedGoogle Scholar
  • 22 Lee CD, Mann KG. Activation/inactivation of human factor V by plasmin. Blood 1989; 73: 185-190.
    PubMedGoogle Scholar
  • 23 Samis JA. et al. Time-dependent association between coagulation factor inactivation and increased elastase during experimental sepsis. J Thromb Haemost 2009; 7: 1032-1034.
    CrossrefPubMedGoogle Scholar
  • 24 Samis JA. et al. Factor V cleavage and inactivation are temporally associated with elevated elastase during experimental sepsis. J Thromb Haemost 2007; 5: 2559-2561.
    CrossrefPubMedGoogle Scholar
  • 25 Gando S. et al. Scientific, Standardization Committee on DICotISoT, Haemostasis. Differentiating disseminated intravascular coagulation (DIC) with the fibrinolytic phenotype from coagulopathy of trauma and acute coagulopathy of trauma-shock (COT/ACOTS). J Thromb Haemost 2013; 11: 826-835.
    CrossrefPubMedGoogle Scholar
  • 26 Mischke R, Wolling H. Influence of fibrinogen degradation products on thrombin time, activated partial thromboplastin time and prothrombin time of canine plasma. Haemostasis 2000; 30: 123-130.
    PubMedGoogle Scholar
  • 27 Tiedje V. et al. The role of fibrinogen plasma levels, the -455G>A fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis. Thromb Haemost 2011; 106: 908-913.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Riedl J. et al. Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS). Thromb Haemost 2014; 111: 670-678.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Bell AJ. et al. Reversal of coagulopathy in Kasabach-Merritt syndrome with tranexamic acid. Scand J Haematol 1986; 37: 248-252.
    PubMedGoogle Scholar
  • 30 Ontachi Y. et al. Kasabach-Merritt syndrome associated with giant liver hemangioma: the effect of combined therapy with danaparoid sodium and tranexamic acid. Haematologica 2005; 90 (Suppl) ECR29.
    PubMedGoogle Scholar
  • 31 Hanna BD, Bernstein M. Tranexamic acid in the treatment of Kasabach-Merritt syndrome in infants. Am J Ped Hematol Oncol 1989; 11: 191-195.
    PubMedGoogle Scholar
  • 32 Watzke HH. et al. Giant hemangioma of the liver (Kasabach-Merritt syndrome): successful suppression of intravascular coagulation permitting surgical removal. J Clin Gastroenterol 1989; 11: 347-350.
    CrossrefPubMedGoogle Scholar
  • 33 Koseki M. et al. Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. Intern J Hematol 2007; 86: 403-406.
    PubMedGoogle Scholar
  • 34 Seto AH, Dunlap DS. Tranexamic acid in oncology. Ann Pharmacotherap 1996; 30: 868-870.
    PubMedGoogle Scholar
  • 35 Marti-Carvajal AJ. et al. Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. Cochrane Database System Rev 2011; 6: CD008562.
    PubMedGoogle Scholar
  • 36 Ignatowicz A. et al. Large myxoma of the left atrium presenting as systemic inflammatory syndrome - a case report. Kardiologia Polska 2008; 66: 903-905.
    PubMedGoogle Scholar
  • 37 Roberts I. et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess 2013; 17: 1-79.
    CrossrefPubMedGoogle Scholar
  • 38 Bennett B. et al. Tumour cell u-PA as a cause of fibrinolytic bleeding in metastatic disease. Br J Haematol 1997; 99: 570-574.
    CrossrefPubMedGoogle Scholar
  • 39 Meijer K. et al. Hyperfibrinogenolysis in disseminated adenocarcinoma. Blood Coagul Fibrinol 1998; 9: 279-283.
    CrossrefPubMedGoogle Scholar